3 Injectable Sulfas

3 SULFAS is an injectable solution made with Sulfamethazine, Sulfamerazine and Sulfadiazine, whose antibiotic combination has greater solubility, lower renal toxicity and a broader spectrum of antibacterial action, acting against gram-positive and gram-negative bacteria that cause digestive, respiratory, genitourinary, mammary gland, locomotor system and septicemic diseases in cattle, horses, sheep, pigs, birds and dogs.

Antibiotic
Sulfamethazine, sulfamerazine and sulfadiazine

MECHANISM OF ACTION: Three Sulfas exhibit a mechanism of action based on the occupation of para-aminobenzoic acid (PABA) receptors, preventing bacteria from incorporating folic acid and the growth factors they require into their metabolism and cannot synthesize. They also inhibit bacterial aerobic and anaerobic respiration.

PHARMACOKINETICS

When administered parenterally or orally, three Sulfas exhibit excellent absorption. They enter the bloodstream, distribute throughout the body, and bind to plasma albumin. They diffuse rapidly, reaching high concentrations in extraplasmatic fluids, allowing the elimination of bacterial infections, most of which are extravascular. They also diffuse easily into the fetus and fetal membranes, and are found in lower concentrations in the central nervous system, bones, and adipose tissue. They are metabolized in the liver and excreted by glomerular filtration and tubular secretion in the kidneys. Smaller amounts are eliminated in feces, bile, pancreatic juice, gastric juice, saliva, and milk.

IMPORTANCE

The importance of 3 SULFAS lies in the fact that the combination of SULFAS it contains provides greater solubility, better absorption, less renal toxic effect and a broader spectrum of antibacterial action against gram-positive and gram-negative bacteria, which cause digestive, respiratory, genitourinary, mammary gland, locomotor system and septicemic diseases in cattle, horses, sheep, pigs, birds and dogs.

INDICATIONS

3 SULFAs are indicated for the treatment of infections of the respiratory tract (pneumonia, bronchopneumonia, etc.), the gastrointestinal tract (colibacillosis), the upper and lower urinary tract, the genital tract (septic metritis, placental retention), the locomotor system (gabarro), the mammary gland (acute and chronic mastitis) and other infections that affect cattle, sheep, goats, pigs (hemorrhagic septicemia, necrotic enteritis), canines (pneumonia, bacillary diarrhea and complications of canine distemper) and birds (coccidiosis, salmonellosis and fowl cholera).

ROUTE OF ADMINISTRATION AND DOSAGE:

• Intravenous: In cattle, horses, sheep, goats and dogs.
• Intramuscular: In pigs
• Oral in drinking water: In birds

The dosage depends on the particular case, however, in general terms the recommended dosage is:

• Equines and Bovines: 50 mL of 3 SULFAs per 100 kg intravenously (100 mg/kg of weight).
• Pigs, Sheep and Goats: 7 mL of 3 SULFAS' per 10 kg (140 mg/kg weight).
• In Dogs and Cats: 3.5 to 7 mL of 3 SULFAS per 10 kg via slow intravenous route (70 - 140 mg per kg of weight).
• In birds, the dose will depend on the route of administration: Intramuscular: 0.5 mL of 3 SULFAS per 1 kg. Drinking water: 5 mL of 3 SULFAS per liter of drinking water for 2 to 3 days of treatment, followed by a 2 to 3-day break, and then repeating the administration every 2 to 3 more days. Respiratory problems: 100 mg/kg. Digestive problems: 50 mg/kg of body weight.

CONTRAINDICATIONS

It should not be used in animals that show liver or kidney damage, blood dyscrasias, or a history of hypersensitivity to sulfonamides.

Do not use in horses intended for human consumption. Due to its potential for urine crystallization, it is advisable to avoid use in dogs with a history of urolithiasis or at high risk of developing urolithiasis.

ADVERSE EFFECTS

In dogs, dry keratoconjunctivitis (which may not be reversible), acute neutrophilic hepatitis, anorexia, diarrhea, fever, hemolytic anemia, urticaria, polyatritis, facial swelling, polydipsia, polyuria, and cholestasis may occur . Potentiated sulfonamides may cause hypothyroidism in dogs, particularly with extended therapy. Acute type I or type II hypersensitivities may rarely occur. Other hematologic effects (anemia, agranulocytosis) are possible but very rare. Adverse effects in cats may include anorexia, leukopenia, and anemia. In horses, transient pruritus may occur after intravenous administration.

OVERDOSE

Overdose manifestations may include gastrointestinal clinical signs (nausea, vomiting, diarrhea), CNS toxicity (depression, headache, and confusion), facial swelling, bone marrow aplasia, and elevated serum aminotransferases. Blood cell counts should be monitored closely.

DRUG INTERACTIONS

The use of antacids may decrease the bioavailability of sulfonamides if administered concomitantly. Concomitant cyclosporine may increase the risk of toxicity. The use of diuretics may increase the risk of thrombocytopenia.

Sulfonamides may displace methotrexate from plasma proteins and increase the risk of toxic effects. Sulfonamides may increase the half-life of methotrexate. Phenytoin. Sulfonamides may decrease the effectiveness of tricyclic antidepressants. Sulfonamides may prolong INR/PT times when used with warfarin.

WARNINGS

This product is for veterinary use only ; do not use on humans. Store below 25°C and away from sunlight. Keep out of reach of children.

WITHDRAWAL PERIOD: 5 days on meat and milk.

PRESENTATION: 100, 250 and 500 ml bottles.

FORMULA:

Each 100 mL contains:

Sulfamethazine: 6.66 g, Sulfamerazine: 6.66 g Sulfadiazine: 6.66 g, Sterile distilled water cbp: 100.00 ml